




>>Entry Name: Miltefosine, BAN, INN

Synonym(s): 2-[[[Hexadecyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethylethanaminium inner salt, 9Cl. Hexadecylphosphocholine. Hexadecyl 2-(N,N,N-trimethylamino)ethyl phosphate. Miltex. D-18506



CAS Registry Number: 58066-85-6

Molecular Formula: C₂₁H₄₆NO₄P

Molecular Weight: 407.572

Accurate Mass: 407.316446

Percentage Composition: C 61.89%; H 11.38%; N 3.44%; O 15.70%; P 7.60%

Use/Importance: Antineoplastic agent. Exerts activity by disruption of cell-membrane function. Potentiates antineoplastic activity of cyclophosphamide

Development Status: Launched 1993 (Germany)

Melting Point: Mp 232-234 dec.°

Sigma: H6772

References:

- Koatze, U. *et al.*, *Chem. Phys. Lipids*, 1980, **27**, 263, (*synth*)
Murai, R. *et al.*, *J.O.C.*, 1982, **47**, 2158, (*cmr*)
Hansen, W.J. *et al.*, *Lipids*, 1982, **17**, 453, (*synth, ir, cmr*)
Nuhn, P. *et al.*, *Pharmazie*, 1982, **37**, 706, (*synth*)
Breiser, A. *et al.*, *Lipids*, 1987, **22**, 925, (*metab*)
Eibl, H. *et al.*, *Cancer Treat. Rev.*, 1990, **17**, 233, (*rev*)
Macdonald, P.M. *et al.*, *Langmuir*, 1991, **7**, 2602, (*synth, pmr*)
Unger, C. *et al.*, *Lipids*, 1991, **26**, 1412, (*rev, clin trial*)
Eibl, H. *et al.*, *Prog. Exp. Tumor Res.*, 1992, **34**, 1, (*synth*)
Martindale, The Extra Pharmacopoeia, 30th edn., Pharmaceutical Press, 1993, 492
Beckers, T. *et al.*, *Eur. J. Cancer, Part A*, 1994, **30**, 2143, (*pharmacol*)
Stekar, J. *et al.*, *Eur. J. Cancer, Part A*, 1995, **31**, 372, (*pharmacol*)